Has Alexandra Gutierrez, MD received payments from drug or device companies?

Yes. Drug and device makers reported $109,004 in general payments to Alexandra Gutierrez, MD across 470 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Alexandra Gutierrez, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Alexandra Gutierrez, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Alexandra Gutierrez, MD

Gastroenterology · New York, NYNPI 1013981737

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $80,030 of the $109,004 with a category attached, or 73.4%. 17 manufacturers reported payments, led by Johnson & Johnson at 50.5% of the total. Reporting peaked in 2019 at $60,249 and has fallen 53.3% since, to $28,126 in 2025. Among gastroenterology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$109,004in general payments, 2019–2025

Across 470 payments — averaging $231.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$55K
Pfizer$30K
AbbVie$22K
Takeda Pharmaceuticals U.S.A., Inc.$581
Lilly USA, LLC$255
Janssen Scientific Affairs, LLC$232
plus $574 from 11 others

$478,900in research payments, 2019–2025

Across 204 payments — averaging $2347.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AbbVie$355K
Takeda Pharmaceuticals U.S.A., Inc.$46K
Boehringer Ingelheim$45K
Janssen Research & Development, LLC$32K
Boehringer Ingelheim RCV GmbH & Co KG$1K

What the payments were for

Consulting fees$8,0507%
Speaking & faculty fees$80,03073%
Travel & lodging$9,9819%
Food & beverage$10,72410%
Education$2190%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson(2 entities)	133	$55,100
Pfizer	54	$30,260
AbbVie	225	$22,003
Takeda Pharmaceuticals U.S.A., Inc.	27	$581
Lilly USA, LLC	12	$255
Janssen Scientific Affairs, LLC	3	$232
Bristol Myers Squibb	2	$145
Covidien LP	1	$124
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	3	$67
Celltrion USA Inc.	2	$42
Boehringer Ingelheim	2	$38
Amgen	1	$33
QOL Medical, LLC	1	$28
Medtronic	1	$28
Shionogi Inc	1	$25
Aimmune Therapeutics, Inc.	1	$24
Sanofi	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Tremfya$41,454
XELJANZ$29,808
STELARA$27,915
Humira$12,464
ZEPOSIA$125
Cytosponge$124

How this compares

$109,004 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York →

Medicare billing

Part B allowed, 2024

$20,924

Medicare patients

Services billed

153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Mesalamine	31	$8,523
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates	77	$4,035
Sulfasalazine	17	$806
LoperamideLoperamide Hcl	14	$737
Omeprazole	22	$363
Folic Acid	30	$206
Pantoprazole Sodium	13	$186
Metronidazole	11	$149
M-Natal PlusPnv,calcium 72/Iron/Folic Acid	12	$59

Paid to pharmacies, not to this prescriber.

Other gastroenterology in New York

David Carr LockeNew York$2M
Arthur KornbluthNew York$1.9M
Sonal KumarNew York$1M
David PoppersNew York$939K
Ellen ScherlNew York$857K
Bruce SandsNew York$810K
Jean Frederick ColombelNew York$786K
Seth GrossNew York$624K
Caterina Oneto ArayaNew York$610K
Dana LukinNew York$491K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →